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Abstract
The maturation of dendritic cells (DCs) allows these antigen-presenting cells to initiate immunity. We pursued this concept in situ by studying the adjuvant action of -galactosylceramide
(GalCer) in mice. A single i.v. injection of glycolipid induced the full maturation of splenic
DCs, beginning within 4 h. Maturation was manifest by marked increases in costimulator and
major histocompatibility complex class II expression, interferon (IFN)- production, and stimulation of the mixed leukocyte reaction. These changes were not induced directly by GalCer
but required natural killer T (NKT) cells acting independently of the MyD88 adaptor protein.
To establish that DC maturation was responsible for the adjuvant role of GalCer, mice were
given GalCer together with soluble or cell-associated ovalbumin antigen. Th1 type CD4
and CD8 T cell responses developed, and the mice became resistant to challenge with ovalbumin-expressing tumor. DCs from mice given ovalbumin plus adjuvant, but not the non-DCs,
stimulated ovalbumin-specific proliferative responses and importantly, induced antigen-specific, IFN- producing, CD4 and CD8 T cells upon transfer into naive animals. In the latter
instance, immune priming did not require further exposure to ovalbumin, GalCer, NKT, or
NK cells. Therefore a single dose of GalCer i.v. rapidly stimulates the full maturation of DCs
in situ, and this accounts for the induction of combined Th1 CD4 and CD8 T cell immunity to a coadministered protein.
Key words: -galactosylceramide • dendritic cell maturation • dendritic cells • exogenous
pathway • T cell–mediated immunity

Introduction
It is important to identify new immune adjuvants to improve the efficacy of vaccines against human tumors and
many infectious diseases such as tuberculosis, malaria, and
AIDS (1, 2). Available adjuvants, like alum and CFA, are
suboptimal in that alum can polarize the immune response
toward a Th2 type (3), while CFA can induce suppressive
macrophages (4) and cytokines (5).
Adjuvants potentially could act at many sites in the immune response, e.g., directly on T cells (6) or on DCs (7).
DCs charged with antigens ex vivo are able to induce adaptive immunity upon injection into rodents and humans,
both CD4 and CD8 T cells. To do so, the injected DCs
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need to be stimulated ex vivo to undergo an intricate differentiation process termed maturation (8–12). In this
way, the injected antigen-bearing mature DCs serve as
“nature’s adjuvants.”
It would be desirable to identify adjuvants that would
harness the DC system directly in situ for the purpose of
controlling immunity. For example DCs are specialized to
present nonreplicating antigens on MHC class I products to
CD8 T cells (for reviews, see references 13 and 14). DC
stimulation through toll-like receptors (15–17) and by
CD4 T cells (18, 19) induces some features of DC maturation in vivo. In recent experiments, antigen also has been
targeted selectively to DCs in vivo together with an agonistic anti-CD40 antibody to stimulate differentiation of DCs
and many other cell types. The combination of antigen targeting to DCs combined with anti-CD40 leads to strong
Th1 CD4 (20) and CD8 (21, 22) T cell responses. The
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presentation of antigen leading to the induction of effector
T cells and memory is consistent with the full maturation
of DCs. While these approaches draw a correlation between DC maturation and the development of immunity,
it remains to be shown directly that antigen-capturing maturing DCs in vivo are the mediators of immunization.
The synthetic glycolipid -galactosylceramide (GalCer)* enhances resistance to tumors (23–26) and several intracellular infections (27–29). The glycolipid is presented to
NKT cells by CD1d molecules particularly on DCs (30).
Presentation by DCs leads to a rapid innate response and
then a more prolonged production of IFN- by the NKT
cells (31). It is also known that GalCer acts as an adjuvant
for CD8 T cell–dependent protection against malaria infection, when the glycolipid is administered together with
an irradiated sporozoite vaccine (32). These results are surprising because GalCer has been used to reduce T cell–
mediated autoimmune diseases (33–38). The mechanism of
adjuvant action of GalCer is therefore of interest to decipher, especially in the contexts of adjuvant action and DC
maturation. Also this glycolipid appears to lack major toxicity in humans and may be useful in the design of vaccines
and therapies (39). In this paper, we describe the capacity
of GalCer to act as a stimulus for the full maturation DCs
in mice, and we show with an adoptive transfer approach
that the mature DCs exclusively mediate the glycolipid’s
role as an adjuvant to help prime antigen-specific, Th1
CD4 and CD8 T cell–mediated immunity.

Materials and Methods
Mice. Pathogen-free C57BL/6 (B6), and TAP/ female
mice at 6–7 wk were purchased from The Jackson Laboratory.
We were generously provided with OT-I and OT-II TCR transgenic mice by Dr. F. Carbone (University of Melbourne,
Parkville, Victoria, Australia), MyD88/ mice by Dr. S. Akira
(Osaka University, Osaka, Japan), and J281/ mice by Dr. M.
Taniguchi (Chiba University, Chiba, Japan). Mice were maintained under specific pathogen-free conditions in the animal facility of the Rockefeller University. All experiments were done in
compliance with relevant laws and institutional guidelines.
Reagents. GalCer (2S, 3S, 4R-1-O(a-galactopyranosyl)2(N-hexacosanoylamino)-1,3,4-octadecanetriol) was provided
by the Pharmaceutical Research Laboratory, Kirin Brewery
(Gunma, Japan) and diluted in PBS. OVA protein was purchased from Seikagaku Corp. LPS was purchased from SigmaAldrich, and CpG-DNA from TriLink BioTechnologies. The
following mAbs were purchased from BD Biosciences: FITCconjugated anti-CD8 or PE-conjugated anti-CD11c, CD44,
CD62L, biotinylated-isotype control, anti-CD40, CD80, CD86,
I-Ab, and V2. Biotinylated mAbs were detected with streptavidin-APC. The following mAbs were purified from hybridoma
culture supernatants: anti-CD4, anti-CD8, anti-DEC205, and
agonistic FGK45.5 anti-CD40 Ab. Rabbit polyclonal anti-asialo
GM1, rabbit-IgG, and rat-IgG were purchased from Wako Pure
Chemical USA Industries and Jackson ImmunoResearch Laboratories, respectively.
*Abbreviations used in this paper: TLR, Toll-like receptor; MLR, mixed
leukocyte reaction; GalCer, -galactosylceramide.
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Flow Cytometry. Cells were preincubated with 2.4G2 culture
supernatant to block Fc receptors, then washed and incubated
with the indicated mAb conjugates for 30 min. Cells were
washed and analyzed on a FACSCalibur™ flow cytometer (Becton Dickinson). For intracellular cytokine staining by FACS®,
5  106 spleen cells were cultured in 24-well plates for 6 or 8 h in
the absence or presence of 1 M OVA257–264 peptide (for CD8
T cells), or 2 M OVA323–339 peptide (for CD4 T cells) with
GolgiPlug (BD Biosciences) to accumulate cytokines intracellularly. The cells were incubated for 15 min at 4C with the 2.4G2
anti-FcR mAb to block nonspecific staining. Then we stained
cells with anti-CD4 or anti-CD8-FITC, or V2-biotin and
streptavidin-APC, for 20 min at room temperature. The cells
were permeabilized using Cytofix/Cytoperm Plus™ (BD Biosciences) and stained with PE-conjugated anti-IFN- (XMG1.2)
or anti-IL-4 (11B11) mAb for 15 min at room temperature. Flow
cytometry used a FACSCalibur™ instrument and CELLQuest™
software (BD Biosciences) or FlowJo (Tree Star).
DC Preparation from Spleen. DCs were isolated from spleens
using prior methods (40). In brief, splenocytes were released by
homogenization followed by treatment with collagenase (collagenase D; Roche Diagnostics Corporation). A DC-enriched cell
population was obtained as a low-density cell fraction using gradients. Collagenase-treated spleens were suspended in a dense
BSA solution, overlaid with 1 ml of PBS, and centrifuged for 30
min. We separated low density CD11c and CD11c fractions
using anti-CD11c coated magnetic beads (Miltenyi Biotech). To
isolate DC subsets on the basis of CD8 expression (41), we first
depleted the low density spleen cells of CD5 and CD19 lymphocytes (T and B cells) with magnetic beads. From the lymphocyte-negative fraction, we selected CD8 and then CD11c cells
(CD8 DCs). No difference in viability was observed between
CD8 and CD8 DCs.
Cytokine Production by DCs. After mice were given GalCer,
LPS, or PBS i.v., CD11c and CD11c cells were isolated with
anti-CD11c magnetic beads and cultured at 2  105 or 3  105
cells/well for 48–72 h in the absence or presence of FGK45.5
anti-CD40 mAb (10 g/ml). The titers of IFN-, IL-4, IL-10,
IL-12p40, and IL-18 in the culture supernatants were determined
by OptEIA™ Kit (BD Biosciences), and IL-12p70 was determined by Quantikine ELISA kit (R&D Systems).
Stimulation of the Mixed Leukocyte Reaction by DCs. Spleen
DCs were isolated using anti-CD11c magnetic beads 8 h after
administration of GalCer, LPS, or PBS. Graded numbers of
spleen DCs from C57BL/6 mice were irradiated and cultured
with 2  105 allogeneic BALB/C or syngeneic T cells, isolated
using T cell enrichment columns (R&D Systems), in a 96-well
flat-bottom plate for 88 h. During the final 16 h, 3H-thymidine
(1 Ci/well) was added. In some experiments, DCs were fixed
with 0.75% paraformaldehyde (Electron Microscopy Science) for
30 min on ice.
DC Presentation of OVA. To assess the role of GalCer as an
adjuvant for a T cell–mediated immune response, we used OVA
as antigen in part because antigen presentation can be readily
monitored using CD4 and CD8 OVA-specific TCR transgenic T cells. OVA was administered to mice i.v. either as a soluble protein (where 5 mg was required) or in association with dying osmotically shocked, syngeneic, TAP/ splenocytes (where
only 1 g was associated with the injected cells; the dying cells
efficiently target to DCs in spleen, accounting for the high efficiency of presentation as described [42]). Briefly, spleen cells were
incubated with hypertonic medium at 37C in the presence or
absence of 10 mg/ml OVA for 10 min, and further incubated
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with hypotonic medium for 2 min to induce apoptosis, followed
by washing with cold PBS (42). After injection of OVA in either
soluble or cell-associated forms, the following tests for antigen
presentation were done. (a) CD11c DC-enriched and CD11c
DC-depleted spleen cells were isolated 4 h after OVA injection
and used to stimulate proliferation of OT-I or OT-II T cells in
culture as described (42). (b) 7 d after OVA injection, mice were
tested for T cell priming by quantifying OVA-specific, IFN-
and IL-4 producing T cells in the spleen as described above. (c)
Mice were given 106 OT-I OVA-specific T cells i.v. and 1 d later
the animals were primed with OVA and GalCer; 3 d later, the
OVA-specific T cells were monitored for expansion in cell numbers and intracellular IFN- production (22). (d) CD11c DCenriched and CD11c DC-depleted spleen cells were isolated 4 h
after OVA injection and used at a dose of 1 and 10  106 respectively to prime naive recipients, assessed as in approach (b) above.
Tumor Protection Experiments. 2  107 OVA pulsed apoptotic
spleen cells were used to immunize mice, either mice given OT-I
OVA-specific T cells i.v. 1 d earlier or naive animals, (42). 3 d
later, 2  106 EG7, OVA-transduced tumor cells (American
Type Culture Collection; CRL-2113) were inoculated s.c. The
parental non-OVA transduced EL-4 thymoma was used as control tumor. To identify protective cells, we used blocking antibodies given i.p. 2 d before tumor inoculation and every 2 d after. The antibodies were control rat IgG, rat anti-CD4 (GK1.5)
and CD8 (53–6.72), and rabbit anti-asialoGM1 Ab or control
rabbit IgG in PBS. Mice were killed when tumor growth exceeded 400 mm2.
Statistical Analysis. The statistical significance of differences
between the experimental groups was determined by the MannWhitney exact rank sum test.

Results
Maturation of the DC Surface After a Single I.V. Injection of
GalCer. GalCer enhances resistance to tumors and infections and is also presented by DCs to NKT cells (Introduction). We used several criteria to test if GalCer leads
to in vivo maturation of DCs, including their capacity to
simultaneously capture and present antigen to diverse
TCR T cells and induce immunity. After i.v. administration of GalCer, both CD8 and CD8 DC subsets
up-regulated several markers consistent with maturation.
This included molecules involved in T cell costimulation
(CD40, 80, 86), as well as antigen capture and presentation (MHC class II and the DEC-205 endocytic receptor;
Fig. 1 A, compare the tracings for GalCer with the black
tracing for the vehicle control). These responses to glycolipid paralleled those seen with other known stimuli for
DC maturation in vivo (Fig. 1 A), i.e., LPS (15), CpG
deoxyoligonucleotides (16, 17), and agonistic anti-CD40
mAb (20–22).
When the kinetics of the splenic DC response to GalCer was examined, as shown for CD86, maturation was
evident within 4 h, and then began to subside at 48 h, returning to baseline at 72 h (Fig. 1, B and C). Axillary
lymph node DCs from the same mice only showed minimal increases in CD86 and CD40 (Fig. 1 D). The kinetics
of the splenic DC response to GalCer was similar to that
seen with LPS treatment (unpublished data). However,
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GalCer was unable to directly stimulate DC maturation
from bone marrow progenitors in culture, in contrast to
LPS (Fig. 1 E). Therefore, GalCer acts as a rapid and efficient inducer of splenic DC maturation in vivo, comparable in efficacy to other stimuli, but it does not have a direct
effect on DCs, unlike other maturation stimuli.
NKT Cells Mediate DC Maturation in a MyD88-independent Manner. NKT cells respond quickly to the presentation of GalCer on CD1d molecules (43). To address the
role of NKT cells in the rapid maturation of DCs, we
tested mice lacking these T cells because of the deletion of
essential TCR J281 sequences (44). The DCs from
J281/ mice did not mature in response to GalCer in
vivo and expressed comparable levels of CD86 and other
maturation markers (CD40, CD80, MHC II) to wild-type
mice given the PBS vehicle control (Fig. 2 A, left). As a
positive control, DCs from J281/ mice were shown to
mature in response to LPS and express high levels of CD86
(Fig. 2 A, right). We then tested DCs from MyD88/
mice, where MyD88 is an essential adaptor protein for signaling cytokine production via Toll-like receptors (TLRs;
references 45 and 46). The DCs from MyD88/ mice did
respond to GalCer, maturing as effectively as DCs from
wild type mice (Fig. 2 B). DCs from NK cell-depleted animals (using anti-asialoGM1 antibody treatment [31]) also
matured in response to GalCer (Fig. 2 C). Therefore,
GalCer in concert with NKT cells rapidly matures DCs
in situ, as assessed by the surface markers of DCs in spleen,
but the response does not require MyD88-based signaling
or NK cells.
Functional Maturation of GalCer-stimulated DCs. To
demonstrate that DCs from GalCer treated mice could
stimulate resting T cells, we isolated DCs with anti-CD11c
magnetic beads and tested them in some standard assays for
DC maturation, e.g., as stimulators for allogeneic T cells in
the primary mixed leukocyte reaction (MLR). DCs from
all groups of mice (controls and mice treated with GalCer
or LPS) stimulated allogeneic T cell proliferation (Fig. 3 A)
and to a much lesser extent, syngeneic T cell proliferation
(Fig. 3 B). As splenic DCs are able to mature “spontaneously” in culture (47), we also tested DCs that were fixed
in paraformaldehyde immediately upon isolation, to assess
their MLR stimulating activity at the time of isolation. The
fixed DCs from control mice no longer had stimulating activity for the MLR (Fig. 3 C), confirming prior work that
most DCs in a spleen are functionally immature (20–22). In
contrast, fixed DCs from GalCer treated mice were potent stimulators of the allogeneic MLR (Fig. 3 C), suggesting the DCs had matured in the mice before isolation and
fixation. With both live and fixed cells, CD11c spleen
cells lacked MLR stimulating activity at the doses tested
(Fig. 3, A–D, open symbols). To prove that enhanced
MLR stimulation by CD11c DCs was dependent upon
NKT cells, we repeated the experiments on fixed DCs
with J281/ mice. The increase in MLR stimulation was
now ablated (Fig. 3 E).
Maturation stimuli also can prime DCs in vivo to produce large amounts of immune enhancing cytokines such
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as IL-12 (48), IFN- (49), and IFN- (50). We studied
cytokine production by cells from mice stimulated 8 h in
vivo with GalCer i.v., with LPS in comparison. We prepared CD11c DC-enriched and CD11c DC-depleted
cells, and further fractionated the DCs into CD8 and
CD8 subsets. The CD11c DCs contained few contaminating T and NK cells (0.5% CD3 and 0.1% NK1.1;
unpublished data), while the DC subsets (CD8 and
CD8) were obtained after depletion of T cells with antiCD5 (Materials and Methods). CD11c DCs from GalCer treated mice produced very high levels of IFN- (Fig.
270

3 F). As prior work (48) showed that IL-12 production by
DCs requires sequential stimuli from a microbe and then a
T cell, e.g., through CD40 stimulation, we restimulated
the DCs primed to GalCer in vivo with anti-CD40 in
culture. Now the DCs from GalCer primed mice also
produced IL-12 p70, in contrast to DCs from either PBS
or LPS treated mice (Fig. 3, F and G). DCs from PBS,
LPS, and GalCer treated mice all produced IL-12 p40,
possibly because of stimuli arising during their isolation
and culture, but as in the case of IFN-, production of IL12 p40 and p70 were most active in the CD8 DC subset
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Figure 1. Maturation of DC
surface markers with GalCer
and other stimuli in vivo. (A) 24 h
after i.v. administration of LPS
(25 g), CpG ODN (10 g), agonistic anti-CD40 mAb (50 g),
GalCer (2 g), or PBS (black
tracing) to C57BL/6 mice, low
density spleen cells were stained
with PE-CD11c and FITCCD8 (to identify DCs and their
CD8 or CD8 subsets) and
with biotinylated isotype control, anti-CD40, CD80, CD86,
I-Ab, and DEC205/CD205 followed by streptavidin APC. (B
and C) As in (A), but the surface
markers of CD8 or CD8 DCs
were followed at the indicated
time points after i.v. administration of the maturation stimulus;
data shown are for CD86 expression. (D) Minimal up-regulation
of CD40 and CD86 on lymph
node DCs (relative to splenic
DCs) 24 h after -GalCer i.v.
Dotted line is the isotype control, gray shadow is antigen expression at time 0, and bold
black line is CD40 and CD86
stain at 24 h. (E) Inability of
GalCer to induce the maturation of DCs from bone marrow
progenitors, in contrast to LPS,
as shown for up-regulation of
CD86 on CD11c DCs from
day 6–7 in culture.

Figure 2. DC maturation by GalCer in vivo requires NKT cells. (A) Maturation, assessed by increased CD86 expression, did not occur in J281/
mice (lacking NKT cells) exposed to GalCer (left), but did occur with LPS (right). (B) Maturation of DCs from MyD88 / mice in response to
GalCer and LPS, and (C) from mice depleted of NK cells by anti-asialoGM1.

(Fig. 3, F and H). In contrast to these findings with DC
stimulated in vivo with GalCer, Ohteki et al. showed
that the CD8 DC subset from Listeria-infected mice was
more active in IFN- production after stimulation with
IL-12 in vitro (49). We could not detect IL-4 and IL-10
( 10 pg/ml) in DCs from GalCer primed mice (unpublished data). Interestingly, DCs stimulated by LPS in vivo
responded to CD40 restimulation in culture by producing
IL-18 rather than IL-12 (unpublished data). In sum, GalCer matures DCs to produce enhancing cytokines and to
more actively stimulate quiescent T cells in the mixed
leukocyte reaction.
DCs Responding to OVA plus GalCer Prime CD4 and
CD8 T Cells in Culture. To prove that DC maturation
was associated with enhanced immunogenicity, we next
injected mice with the protein antigen, OVA, either as a
soluble protein or in association with dying TAP/ splenocytes (the TAP/ deletion ensured OVA presentation
by MHC class I of recipient DCs rather than the injected
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splenocytes [21]), without or with GalCer. Then we isolated the DCs and non-DC fractions from spleen and measured their capacity in tissue culture to stimulate CD8
and CD4, OVA-specific, naive OT-I and OT-II, TCR
transgenic T cells respectively (Fig. 4 A). With both soluble (Fig. 4 B) and cell-associated OVA (Fig. 4 C) as antigen, the DCs selectively and actively stimulated proliferative responses by the naive CD4 and CD8 T cells in
culture; CD11c cells were inactive (Fig. 4, B and C). The
T cells produced substantial IFN-, 10 ng/ml culture,
but no detectable IL-4 (unpublished data), indicating that
antigen-capturing DCs were able to polarize the Th1 type
of T cell differentiation.
The apparent lack of T cell stimulating activity in the
CD11c fractions was puzzling, because these cells should
include marginal zone B cells that express high levels of
CD1d (51, 52) and are activated by GalCer in vivo (53).
Therefore, in the OVA experiments of Fig. 4, we also enriched CD19 CD21 CD23 marginal zone B cells and
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Figure 3. Functional maturation of splenic DCs from GalCer
treated mice. 8 h after i.v. administration of GalCer, LPS or
PBS, as in Fig. 1, spleen DCs
were isolated using anti-CD11c–
coated magnetic beads (purity
95 2%). Graded numbers of
spleen DCs from C57BL/6 mice
were irradiated (30 Gy) and
added to 2  105 allogeneic
BALB/c (A) or syngeneic (B) T
cells for 3 d in flat bottomed 96well plates. In parallel, DCs were
fixed with paraformaldehyde for
30 min, to block their maturation during the mixed leukocyte
reaction, and also irradiated, followed by addition to allogeneic
(C) and syngeneic (D) T cells.
Proliferative responses were
measured by [3H]-thymidine
incorporation (Materials and
Methods). The results are representative of four independent
experiments. In E, the experiment in B was repeated comparing fixed DCs from wild-type
and J281/ NKT deficient
mice given GalCer or vehicle.
The results are averages of three
independent experiments. (F and
G) Mice were given PBS,
GalCer, or LPS i.v. and 8 h
later, CD11c DC enriched and
CD11c DC-depleted, low density spleen cells were isolated
with -CD11c coated magnetic beads. In parallel, to test cytokine production by DC subsets, the low density spleen cells were first lymphocyte depleted
with CD5 and CD19 magnetic beads, and then CD8 and CD11c cells were selected successively with magnetic beads, providing enriched CD8
and CD8 DC subsets respectively. IFN- secretion (pg/ml) by each cell subset was measured by ELISA assays after culturing the cells for 48 h without
further stimulation in 96 well plates at 2  105/well (F), while IL-12 production was measured in cells cultured 72 h in the presence of 10 g/ml agonistic FGK45.5 anti-CD40 antibody at 3  105/well (G and H). All results required pools of three mice and represent averages of three independent experiments (*P 0.05).

CD19 CD21 CD23 follicular B cells. We confirmed
that the former had higher levels of CD1d and that both
types of B cell up-regulated CD86 in response to GalCer
(Fig. 4 D, left part of figure). Both B cell types failed to
present OVA (Fig. 4 D, right part of figure), especially
when compared with the CD11c DCs isolated from these
same animals (Fig. 4 B). Thus, DCs are the major cell type
that acquires stimulating activity for naive T cells in response to the combined administration of a foreign protein
and GalCer.
OVA Together with GalCer as Adjuvant Primes CD8 T
Cells In Vivo and Increases Resistance to OVA-expressing Tumors. To monitor the activation of OVA-specific CD8
T cells more directly in vivo, mice were injected i.v. with
106 CFSE-labeled CD8, OVA-specific, TCR transgenic
T cells. 1 d later, OVA-loaded splenocytes were given
without or with GalCer. 3 d after injection of the OVAloaded splenocytes, there was extensive expansion of the
injected OT-I T cells and dilution of the CFSE label (proliferation). The injection of GalCer together with antigen
increased the frequency of cells in the spleen by threefold
272

(Fig. 5 B) and induced them to express high levels of the
activation antigen CD44 (unpublished data). The spleen
cells were also cultured with or without OVA peptide to
determine if the T cells, gated for expression of the V2
OT-I TCR, had been primed to produce IFN-. The use
of the GalCer adjuvant induced high level IFN- production in most OT-I T cells (Fig. 5 B), but no detectable
IL-4 (unpublished data). To verify that GalCer-dependent priming was associated with enhanced resistance to
OVA-expressing tumors, we gave mice 106 OT-I T cells
i.v. and 1 d later, we administered GalCer and OVAloaded cells also i.v. 3 d later, we injected 2  106 EG7
cells into the skin, where EG7 is a murine thymoma transduced to express OVA in a secretory form. The mice
primed with TAP/ / OVA and GalCer showed strong
resistance to the tumor, whereas mice primed with TAP//
OVA splenocytes alone showed some resistance, but the
EG7 tumors recurred (Fig. 5 C). We repeated the experiments in mice depleted of CD8 or CD4 T cells with
monoclonal antibodies, or NK cells with anti-asialo GM1
(these depletions were begun 1 d after administering Gal-
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Figure 4. DCs capturing OVA protein and matured by GalCer in vivo efficiently stimulate naive CD4 and CD8 T cells in culture. (A) Schematics
for the experiments in Figs. 4, 6, and 7. Mice were given GalCer or vehicle (PBS) together with OVA protein (5 mg/mouse) i.v. or osmotically
shocked syngeneic splenocytes loaded with OVA protein as described (reference 21). 4 h later, CD11c cells or CD11c cells were isolated and tested for
their capacity to stimulate CD8 and CD4 TCR transgenic T cells from OT-I and OT-II mice, respectively. T cell proliferation was measured after
[3H]-thymidine at 36–48 h. In some experiments (Fig. 5), OVA-specific T cell responses in spleen were evaluated 1 wk after immunization, while in others (Fig. 7), CD11c cells were transferred into naive mice to prime T cells in vivo. (B and C) The responses of CD4 (OT-II) and CD8 (OT-I) T cells
to CD11c (top) and CD11c (bottom) spleen cells from mice given soluble OVA (left panels) or cell-associated OVA (right panels) in the absence or
presence of GalCer; representative of three independent experiments. (D) As in B, but enriched populations of CD21high marginal zone B cells and
CD21low follicular B cells were isolated by cell sorting and studied for CD1d and CD86 expression, as well as presentation of the injected soluble OVA to
OT-I T cells. CD21high marginal zone B cells are the upper group of data on the right, while CD21low follicular B cells are the lower group (note much
lower values on y-axis for D vs. B and C).

Cer to allow time for the NKT cells, which express CD4,
to mature the DCs). Only CD8 depletion ablated the resistance induced by OVA-loaded splenocytes together with
GalCer (Fig. 5 D).
273
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To determine if GalCer could serve as an adjuvant for
generating specific CD4 or CD8 T cell responses to
OVA in naive animals, we injected 2  107 dying cells
loaded with OVA i.v., and half the animals also received
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GalCer. 7 d later, we tested if splenic T cells would secrete IFN- in response to rechallenge with OVA peptides presented on MHC class I or II products (Fig. 4 A for
diagram of protocol). GalCer did serve as an adjuvant to
prime CD4 and CD8 T cells in vivo, as illustrated by
intracellular cytokine staining for IFN- in Fig. 6 A and
summarized in Fig. 6 B. IL-4 production was not detectable (unpublished data). When we tried to prime J281/
mice lacking NKT cells; however, GalCer no longer
274

served as an adjuvant (Fig. 6 B, bottom). To establish that
the observed T cell immunity in wild-type mice was associated with protective resistance, we verified that naive
mice immunized with the combination of TAP//OVA
splenocytes and GalCer showed resistance to OVAtransduced EG7 tumor cells, but no resistance to the parent EL-4 thymoma that was not transduced to express
OVA (Fig. 6 C, compare left and right panels). In summary, a single intravenous dose of GalCer acts as an adju-
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Figure 5. GalCer enhances
immunity to OVA-bearing DCs
in vivo. (A and B) 1 d after transferring 106 CFSE-labeled OT-I
cells i.v. into C57BL/6 mice,
four groups of mice were given
either no treatment, osmotically
shocked and OVA loaded
TAP/ spleen cells, GalCer
(2 g/mouse), or both OVA
loaded spleen cells and GalCer.
3 d later, spleen cells were monitored for dilution of fluorescence
in the CFSE labeled V2 OT-I
cells in the spleen. IFN- production was monitored in tandem after culturing the spleen
cells without or with OVA257–264
(1 M) for 6 h in the presence of
GolgiPlug. Each panel shows the
percentage of cytokine producing, CFSE-labeled, V2 cells in
the spleen. (C and D) At day 3
after immunization as in A and
B, the mice were injected s.c.
with EG7 tumor cells, which
stably express OVA as a secreted
protein. Mean tumor sizes at 2 d
intervals were plotted on the left,
and the distribution of tumor
sizes at day 18 in the individual
animals shown on the right. The
experiments in the bottom panels were similar to those in the
top except that mice were immunized with OVA loaded
spleen cells and GalCer but depleted of individual lymphocyte
subsets (from 2 d before tumor
inoculation to the end of the experiments) with monoclonal antibodies as indicated.

Figure 6. Induction of strong
immunity in naive mice with
cell associated OVA together
with GalCer. (A) Priming of
naive mice with the combination
of 2  107 OVA-loaded, TAP/
spleen cells and GalCer (2 g/
mouse) i.v. 7 d later, spleen cells
were cultured without or with
OVA257–264 or OVA323–339 peptides to stimulate OVA specific
CD8 and CD4 T cells respectively and T cell production of
IFN- was measured by intracellular cytokine staining (the frequency of T cells producing IL-4
was 0.04% for all groups). (B)
Same as (A), but means are
shown for four individual mice
(*P
0.05, **P
0.01 for the
wild-type mice primed with
OVA-loaded, TAP/ spleen
cells and GalCer vs. the other
groups). CD4 and CD8 T cell
responses were elicited by
OVA323–339 and OVA257–264 peptides respectively. (C) 1 wk after
immunization in each group,
mice were challenged with either 2  106 EG7 or EL-4 tumor
cells. The data are mean tumor
sizes
SEM of 6 (EG7) or 3–4
(EL4) individual mice in independent experiments. (TAP//
OVA  GalCer vs. the other
groups at day 18; P 0.005).

vant for combined Th1 type CD4 and CD8 T cell immunity in mice.
The Adjuvant Action of GalCer Is Due to Mature DCs.
Given the evidence for T cell responses to the coadministration of protein antigen and GalCer, we wanted to
prove that the mature DCs were responsible for the glycolipid’s adjuvant action. To do so, we again gave mice
OVA antigen as a soluble protein or in association with
dying cells. Then we isolated CD11c DCs from spleen
4 h later and tested their capacity to generate CD4 and
CD8 effector T cells in naive animals (Fig. 4 A for diagram of the protocol). We monitored T cell priming by
looking at day 7 for IFN- production by both T cell subsets using an intracellular cytokine secretion assay performed on lymph node and spleen cells cultured for 6 h
with or without OVA peptides in the presence of brefeldin
A (Materials and Methods).
We first obtained DCs from 4 groups of mice primed
with vehicle, OVA only, GalCer only, or both OVA and
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GalCer. The latter DCs primed IFN- producing CD4
and CD8 T cells in naive mice (Fig. 7, A and B; top panels). The results were virtually identical in spleen (Fig. 7)
and lymph node (unpublished data). Again, no IL-4 producing T cells could be detected (unpublished data). We
were concerned that some of the primed IFN- producing
cells might be NKT cells, but very few of the CD4 and
CD8 cytokine producers labeled for the NK1.1 marker
(unpublished data), presumably because at day 6, the NKT
response to GalCer on DCs has largely subsided (31).
It remained possible that the transferred mature DCs in
Fig. 7 were not priming naive T cells directly, but still required either NK or NKT cells in the recipient animals.
We therefore repeated the experiments but injected the
DCs (from mice primed with OVA splenocytes and GalCer) into three groups of recipients: control mice treated
with rabbit Ig, mice treated with rabbit anti-asialoGM1 to
deplete NK cells (31), and mice depleted of NKT cells
through deletion of the J 281 genetic sequences (44). In
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all cases, the DCs from mice given OVA together with
GalCer were able to prime the recipients (Fig. 7, A and
B; lower rows). Therefore the NKT cell dependent maturation of antigen capturing DCs by GalCer in donor mice
leads to the priming of Th1 CD4 and CD8 effector T
cells in naive recipient animals.

Discussion
Stimuli for the Maturation of DCs In Situ. Most DCs in a
mouse spleen are functionally immature in the steady-state,
but they undergo rapid maturation in response to GalCer.
Several criteria have been used here to document the full
maturation of DCs, which in prior studies has been monitored primarily at the level of increased expression of costimulatory molecules like CD86. Here we have emphasized
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the capacity of DCs in vivo to become potent stimulators of
immunity, the classical criterion for maturation.
A useful functional marker for maturation is enhanced T
cell stimulatory activity in the mixed leukocyte reaction. It
seems that this is best assayed with chemically fixed DCs, as
fixation should prevent DCs from undergoing “spontaneous” maturation in culture (47). When this is done, DCs
from control mice are weak MLR stimulators, whereas
formaldehyde-fixed DCs from GalCer treated mice are
potent. This maturation criterion is fully dependent upon
NKT cells. It has also been reported that some features of
DC maturation are induced by CD1d-restricted human
NKT cell clones in vitro (54).
Maturation of DCs in mice also has been achieved by
stimuli for toll like receptors, e.g., LPS (15) and CpG oligodeoxynucleotides (16, 17). Likewise TCR T cells in-
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Figure 7. DCs isolated from
mice given OVA together with
GalCer are able to prime naive
animals. Mice were given GalCer or vehicle together with either OVA protein (5 mg/mouse)
i.v. (A) or with osmotically
shocked TAP/ splenocytes
without or with OVA loading
(B). 4 h after injection, 106
CD11c DCs from each group
were transferred to naive syngeneic mice. In the top panels, 7 d
after immunization with DCs
but no further antigen or GalCer, spleen cells were cultured
without (open bars) or with
(closed bars) OVA peptides with
GolgiPlug to allow accumulation
of intracellular IFN- as described
in experimental procedures. Intracellular IFN- staining was
performed with double labeling
for CD4 and CD8. In the bottom
panels, the DCs were taken from
mice given GalCer together
with either OVA protein (A) or
OVA loaded splenocytes (B), but
the DCs were injected into either rabbit Ig (control)-treated
mice or mice lacking NKT and
NK cells (see Results) to test
priming of CD4 and CD8,
IFN- producing effector T
cells. The data are mean SEM
of three individual mice in independent experiments. *P 0.05.

duce DC maturation in vivo, as assessed by the up-regulation of surface costimulatory molecules (18, 19). In this
paper, GalCer harnesses NKT cells to fully mature DCs as
evidenced by the induction of immunity to antigens coadministered with the glycolipid. In contrast to T cell–mediated maturation, which is a part of an adaptive immune response, NKT cells are innate cells that mature most of the
DCs in spleen very quickly, within 4 h of administering
GalCer by the intravenous route.
Mechanisms of Maturation via GalCer. The maturation
of DCs after presentation of GalCer to NKT cells seems
to operate independently of TLR signaling. MyD88 is one
of the adaptor proteins for signaling cytokine production
through TLRs, but MyD88 is not required for the maturation of DCs by GalCer. DCs have a MyD88-independent but TLR-dependent maturation pathway, especially
through TLR4 (55, 56). However, this should lead to Th2
type responses (57), whereas DCs matured from GalCer
treated, MyD88 knockout mice induce Th1 type responses
(unpublished data).
Transactivation of NK and B cells following administration of GalCer is well known (58). As a high proportion
of many cell types including DCs are activated in response
to the glycolipid, a “cytokine storm” induced by GalCer
likely is playing a role. However, it is requiring a good deal
of experimentation to identify the mechanisms of NKTdependent DC maturation in vivo, and this will be the subject of a future report.
GalCer as an Adjuvant for Th1 Type Cell-mediated Immunity. It may be surprising that GalCer matures splenic
DCs and also acts as an adjuvant for strong Th1 type CD4
and CD8 T cell responses to antigens given i.v., as numerous reports have used this same compound to suppress
experimental, Th1-dependent autoimmune diseases (33–
38, 59). Naumov et al. have reported that GalCer treatment of autoimmune prone animals induces a form of
tolerogenic DCs in the lymph nodes that drain the target
organ for the autoimmune disease (37). The basis for these
ostensibly major differences in immunologic outcome is
unclear, i.e., polarization in our study to Th1 responses
versus polarization toward Th2 in other studies. However,
the experimental designs are different. We have used a single intravenous dose of glycolipid to activate DCs to produce Th1 polarizing cytokines such as IFN- and IL-12 at
the same time that antigens are given i.v. for presentation
by the maturing DCs. In contrast, repeated doses of GalCer have been given to treat autoimmune prone mice. In
other instances, a multiple dose regimen (60) or the s.c. administration of OVA together with CFA (61), have been
associated with Th2 polarization to external antigens in response to GalCer. A Th2 environment may originate
from the finding that soluble GalCer is able to anergize
NKT cells after the initial cytokine response, such that the
NKT cells can no longer respond to DCs and in particular
to produce IFN- (31).
To document the role of DC maturation for adjuvant
function in vivo, we have isolated the CD11 DCenriched and CD11c DC-depleted populations from the
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spleens after injection of either soluble or cell-associated
OVA antigen in the absence or presence of GalCer.
Strong CD4 and CD8 T cell responses are induced by
DCs from GalCer-treated mice, whereas we do not detect immunogenicity with non-DCs from these animals.
This adoptive transfer approach therefore establishes that
mature DCs are responsible for the in vivo action of adjuvants, since the recipients of the DCs do not require additional exposure to OVA antigen, GalCer adjuvant, or innate NKT and NK cells. In the case of cell-associated
OVA, this antigen is known to induce peripheral tolerance
in the absence of GalCer (21), so that the protective tumor immunity we have observed overrides an otherwise
tolerogenic situation. These data indicate that DCs are necessary and sufficient for the adjuvant role of GalCer, including its capacity to enhance CD8 T cell responses to
nonreplicating forms of a protein antigen. To harness the
adjuvant properties of this glycolipid, however, DCs need
to capture the antigen or vaccine in question and also
present the GalCer to NKT cells.
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